Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MNCs, Corporates to Enter Pharma Retail (India)

This article was originally published in PharmAsia News

Executive Summary

India's drug retail industry may be moving toward consolidation as large Indian companies as well as global players are looking to it for major opportunities. Today India's drug retail market generates 450 billion rupees per year and is handled by around 550,000 operations. Hong Kong-based Zuellig Pharma and U.S.-based Cardinal Health are rumored to be eyeing opportunities to expand in India. Zuellig Pharma is one of Asia's largest drug logistics providers, and views India as "a major market with vast potential," says Nike Ampton, managing director of Zuellig Pharma India. India's Reliance Anil Dhirubhai Ambani Group is investing 12 billion rupees to build a large drug distribution network in India. Reliance Industries retail arm Reliance Retail in India says it may begin purchasing drugs directly from pharmaceutical manufacturers as a way to comb out spurious products. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC066271

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel